-
Metabolic syndrome is common and is associated with an increased risk for CVD and T2DM in both sexes.
-
Acid suppression, particularly with proton pump inhibitors (PPIs) is correlated with an increased risk of community-acquired Clostridium difficile colitis.
-
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout; Prognostic Value of Serial B-Type Natriuretic Peptide Testing During Follow-up of Patients with Unstable Coronary Artery Disease; Dietary Fiber Intake and Risk of Colorectal Cancer
-
Risk of Death in Elderly Users of Conventional vs Atypical Antipsychotic Medications; Beta-Blockers to Prevent Gastroesophageal Varices in Cirrhosis Patients; Effects of Protein, Monounsaturated Fat, and Carbohydrate Intake on Blood Pressure and Serum Lipids
-
The ECG in the Figure was obtained from a 35-year-old man. Is it abnormal? What do you want to know
-
Cyclooxygenase 2 (COX 2) inhibitors may not be as safe as previously thought. These agents have a considerable risk of adverse gastrointestinal events. The concurrent use of ulcer-healing drugs appears to decrease this risk.
-
The strong correlation between reduction of aura symptoms and migraine attacks stresses the potential role of aura-like events and possibly cortical spreading depression as a trigger for trigeminal vascular activation, and subsequently the development of migraine headaches.
-
A very small group of patients consume a significant portion of outpatient primary care physician time.
-
Infliximab, an antibody against tumor necrosis factor, is effective in ulcerative colitis.
-
A new drug has been approved for the treatment of children with below average height who are resistant to growth hormone. Mecasermin is a human insulin-like growth factor-1 (IGF-1) that is produced by recombinant DNA technology. This protein is marketed by Tercica, Incorporated as Increlex.
